{"filings":[{"id":526758,"accession_number":"0001193125-26-230749","cik":1615219,"company_name":"Decoy Therapeutics Inc.","ticker":"DCOY","form_type":"8-K","filed_at":"2026-05-19T20:06:58+00:00","items":["5.08","8.01"],"status":"ready","headline":"Decoy Therapeutics sets July 14, 2026 annual meeting; proposal deadline May 29","event_type":"other","confidence":"high","bullets":["Annual meeting of stockholders scheduled for July 14, 2026; record date May 22, 2026.","Deadline for Rule 14a-8 stockholder proposals is close of business on May 29, 2026.","Deadline for director nominations and other Bylaw business: May 29, 2026.","Universal proxy rule (Rule 14a-19) notices also due by May 29, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94103,"accession_number":"0001193125-26-139145","cik":1615219,"company_name":"Decoy Therapeutics Inc.","ticker":"DCOY","form_type":"8-K","filed_at":"2026-04-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Decoy Therapeutics regains Nasdaq minimum bid price compliance after reverse split","event_type":"regulatory","confidence":"high","bullets":["Nasdaq confirmed compliance on March 31, 2026; Common Stock bid price closed at $7.47 on March 20, 2026.","Reverse stock split effective March 6, 2026, to cure bid price deficiency below $1.00.","Company subject to Mandatory Panel Monitor until March 31, 2027; future non-compliance may trigger delisting.","Hearings Panel granted exception until March 20, 2026; compliance achieved with 10 consecutive days above $1.00."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106225,"accession_number":"0001193125-26-092748","cik":1615219,"company_name":"Decoy Therapeutics Inc.","ticker":"DCOY","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Decoy Therapeutics announces 1-for-12 reverse stock split effective March 6, 2026 to regain Nasdaq compliance","event_type":"other_material","confidence":"high","bullets":["Shares reduced from ~6.38M to ~532,000; authorized shares unchanged at 100M.","Split effective 5:00 p.m. ET on March 6; trading on split-adjusted basis begins March 9.","New CUSIP 79400X602; fractional shares cashed out at closing price on March 6.","Equiniti Trust Company acting as exchange agent; all options and warrants adjusted proportionally.","Stockholders approved reverse split range of 1-for-4 to 1-for-15; Board chose 1-for-12 ratio."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106224,"accession_number":"0001193125-26-068813","cik":1615219,"company_name":"Decoy Therapeutics Inc.","ticker":"DCOY","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Decoy Therapeutics shareholders approve 2026 equity plan and reverse stock split","event_type":"other_material","confidence":"high","bullets":["Approved 2026 Equity Incentive Plan: 351,837 for, 68,978 against, 55,703 abstentions.","Approved reverse stock split of common stock at ratio between 1:4 and 1:15, at board's discretion.","Reverse split proposal: 2,187,125 votes for, 507,474 against, 2,173 abstentions.","Adjournment proposal was unnecessary due to sufficient votes; broker non-votes totaled 2,220,254."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106228,"accession_number":"0001615219-26-000013","cik":1615219,"company_name":"Decoy Therapeutics Inc.","ticker":"DCOY","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["5.03","7.01","8.01","9.01"],"status":"ready","headline":"Salarius Pharmaceuticals renames to Decoy Therapeutics; ticker changes to DCOY effective Jan 8, 2026","event_type":"other_material","confidence":"high","bullets":["Name change to Decoy Therapeutics Inc. and ticker symbol change from SLRX to DCOY effective January 8, 2026.","No change to shares outstanding, shareholder rights, CUSIP number, or transfer agent.","Focus on AI-enabled peptide-conjugate platform; lead antiviral program attracts BARDA interest.","2026 priorities: advance lead into clinic, expand pipeline, pursue partnerships, and strengthen capital structure.","Company to launch new website decoytx.com for investor relations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106227,"accession_number":"0001615219-26-000005","cik":1615219,"company_name":"Decoy Therapeutics Inc.","ticker":"DCOY","form_type":"8-K","filed_at":"2026-01-02T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Salarius receives Nasdaq delisting notice for bid price non-compliance; appeal planned","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Salarius on Dec 31, 2025 that bid price closed below $1.00 for 30 consecutive days.","Company ineligible for 180-day cure period due to reverse stock split within prior year.","Unless appeal filed by Jan 7, 2026, trading suspended Jan 9, 2026 and Form 25-NSE filed.","Salarius intends to appeal to Nasdaq Hearings Panel to stay suspension and present compliance plan.","No assurance that securities will remain listed on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106226,"accession_number":"0001615219-26-000003","cik":1615219,"company_name":"Decoy Therapeutics Inc.","ticker":"DCOY","form_type":"8-K","filed_at":"2026-01-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Salarius shareholders re-elect directors, approve executive compensation, ratify EY as auditor","event_type":"other","confidence":"high","bullets":["Votes for Hanish: 143,525; against: 11,932; abstain: 5,761; broker non-votes: 256,225.","Votes for McVicar: 143,599; against: 10,058; abstain: 7,561; broker non-votes: 256,225.","Advisory vote on executive compensation approved: 132,240 for, 22,606 against, 6,372 abstentions; broker non-votes: 256,225.","Ratification of Ernst & Young LLP as auditor: 401,439 for, 12,132 against, 3,872 abstentions.","Quorum achieved: 417,443 shares present (39.7% of 1,051,782 outstanding)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122521,"accession_number":"0001615219-25-000197","cik":1615219,"company_name":"Decoy Therapeutics Inc.","ticker":"DCOY","form_type":"8-K","filed_at":"2025-12-19T23:59:59+00:00","items":["5.07","7.01","9.01"],"status":"ready","headline":"Salarius annual meeting adjourned due to lack of quorum; reconvened Dec 31","event_type":"other","confidence":"high","bullets":["Only ~30% of shares voted; 34% quorum required; meeting adjourned without business.","Reconvened meeting set for December 31, 2025 at 10:00 a.m. CT via virtual webcast.","Record date remains October 24, 2025; previously submitted proxies remain valid.","Company soliciting additional votes before reconvened meeting; no proposals changed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122520,"accession_number":"0001615219-25-000168","cik":1615219,"company_name":"Decoy Therapeutics Inc.","ticker":"DCOY","form_type":"8-K","filed_at":"2025-11-19T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Salarius Pharma appoints CEO, CSO, CBO with $225k salary and 35% bonus","event_type":"leadership","confidence":"high","bullets":["Frederick E. Pierce appointed CEO, Dr. Barbara Hibner as CSO, Peter Marschel as CBO effective upon merger closing.","Each executive receives annual base salary of $225,000 and target annual bonus of 35% of base salary.","Severance includes $225,000 lump sum plus 9 months COBRA reimbursement if terminated without cause or for good reason.","Employment agreements incorporate at-will status, restrictive covenants, and eligibility for standard benefits."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122519,"accession_number":"0001615219-25-000166","cik":1615219,"company_name":"Decoy Therapeutics Inc.","ticker":"DCOY","form_type":"8-K","filed_at":"2025-11-17T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Salarius Pharmaceuticals corrects false delisting reports; remains listed on Nasdaq","event_type":"regulatory","confidence":"high","bullets":["Company statement that stock continues trading on Nasdaq Capital Market under ticker SLRX despite inaccurate Yahoo Finance and CapIQ delisting reports.","Nasdaq compliance regained: Bid Price Rule (Sep 4, 2025) and Equity Standard (Oct 10, 2025) re-attained.","Merger with Decoy Therapeutics completed Nov 13, 2025; no delisting notification received from Nasdaq.","Company contacted financial data platforms to correct erroneous delisting information."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122518,"accession_number":"0001615219-25-000162","cik":1615219,"company_name":"Decoy Therapeutics Inc.","ticker":"DCOY","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["1.01","2.01","3.02","3.03","5.03","5.02","8.01","9.01"],"status":"ready","headline":"Salarius completes acquisition of Decoy Therapeutics, raises ~$6.3M in public offering","event_type":"m_and_a","confidence":"high","bullets":["Closed merger with Decoy Therapeutics on Nov 12; issued Series A/B Preferred Stock convertible at 2,800:1 ratio post-anti-dilution adjustment.","Public offering priced at $1.50/unit (common + Series A/B warrants); net proceeds ~$6.3M, closed Nov 12.","Frederick Pierce (Decoy CEO) appointed CEO, replacing Mark Rosenblum who remains CFO; Dr. Barbara Hibner as CSO, Peter Marschel as CBO.","Board change: Pierce appointed Class II director; Bruce McCreedy resigned, not due to any disagreement.","Warrants: Series A (5-yr term, $1.50 exercise), Series B (1-yr term, $1.50), Pre-funded ($0.0001). Representative warrants also issued."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122517,"accession_number":"0001615219-25-000148","cik":1615219,"company_name":"Decoy Therapeutics Inc.","ticker":"DCOY","form_type":"8-K","filed_at":"2025-10-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Salarius grants $225K transaction bonus to Acting CEO Rosenblum tied to Decoy merger","event_type":"other_material","confidence":"high","bullets":["Board approved $225,000 cash bonus for Acting CEO/CFO Mark J. Rosenblum.","Bonus payable upon closing of the previously announced merger with Decoy Therapeutics.","Payment subject to Rosenblum's continued employment through the closing date.","Rosenblum holds dual roles as Acting CEO and Executive VP/CFO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122516,"accession_number":"0001615219-25-000145","cik":1615219,"company_name":"Decoy Therapeutics Inc.","ticker":"DCOY","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Salarius regains Nasdaq equity compliance; fully compliant ahead of Decoy merger","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on Oct 10, 2025 confirming compliance with minimum stockholders' equity requirement (Rule 5550(b)(1)).","Now fully compliant with all Nasdaq listing requirements, having also regained bid price compliance on Sept 9, 2025.","Subject to a Mandatory Panel Monitor for one year from Oct 10, 2025; noncompliance could lead to delisting without a cure period.","Planned merger with Decoy Therapeutics (announced Jan 13, 2025) remains on track; combined company to be named Decoy Therapeutics.","Post-merger pipeline includes pan-coronavirus antiviral IND filing within 12 months and data from MD Anderson seclidemstat study."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122515,"accession_number":"0001615219-25-000142","cik":1615219,"company_name":"Decoy Therapeutics Inc.","ticker":"DCOY","form_type":"8-K","filed_at":"2025-10-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Salarius raises $6.2M; believes Nasdaq equity compliance regained ahead of Oct 20 deadline","event_type":"other_material","confidence":"high","bullets":["Raised $2.4M from ATM sales (434,882 shares) and $3.8M from C/M Capital Master Fund purchase agreement.","Believes stockholders' equity now exceeds $2.5M as of Oct 6, 2025; awaiting Nasdaq confirmation.","Previously faced Nasdaq delisting risk if compliance not met by Oct 20, 2025.","Q3 10-Q expected to reflect equity above $2.5M as of Sept 30, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139220,"accession_number":"0001615219-25-000135","cik":1615219,"company_name":"Decoy Therapeutics Inc.","ticker":"DCOY","form_type":"8-K","filed_at":"2025-09-18T23:59:59+00:00","items":["1.01","3.03","9.01"],"status":"ready","headline":"Salarius amends merger deal with Decoy; sets preferred conversion floor at $3.75","event_type":"m_and_a","confidence":"high","bullets":["Fifth Amendment to Merger Agreement sets initial conversion price at $10.50/share for Series A & B Preferred.","Price protection adjusted using spread between $10.50 baseline and any dilutive subsequent financing.","Floor price of $3.75/share set as lowest conversion price in price protection calculations.","Series B Preferred redemption price changed to $10.50 multiplied by 1,000 per share.","All other Merger Agreement terms remain in full force and effect."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139219,"accession_number":"0001615219-25-000125","cik":1615219,"company_name":"Decoy Therapeutics Inc.","ticker":"DCOY","form_type":"8-K","filed_at":"2025-09-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Salarius regains Nasdaq bid price compliance; merger with Decoy ongoing","event_type":"other_material","confidence":"high","bullets":["Regained compliance with Nasdaq's minimum bid price requirement on Sept. 4, 2025.","Subject to one-year Mandatory Panel Monitor; delisting risk if bid price falls below $1.00 again.","Must also comply with Nasdaq equity standard by Oct. 20, 2025; currently noncompliant.","Planned merger with Decoy Therapeutics to combine into Decoy Therapeutics, led by Decoy's co-founders.","Decoy aims to file IND for pan-coronavirus antiviral within 12 months and advance other pipeline programs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139218,"accession_number":"0001615219-25-000119","cik":1615219,"company_name":"Decoy Therapeutics Inc.","ticker":"DCOY","form_type":"8-K","filed_at":"2025-08-27T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Salarius Pharmaceuticals receives Nasdaq extension to regain equity compliance by Oct 20, 2025","event_type":"regulatory","confidence":"high","bullets":["Nasdaq Hearings Panel granted Salarius until October 20, 2025 to comply with the Equity Standard (Rule 5550(b)(1)).","Salarius effected a 1-for-15 reverse stock split on August 15, 2025, targeting compliance with the $1.00 Minimum Bid Price by August 29, 2025.","Previously received a Delisting Notice on April 23, 2025 for noncompliance with the Minimum Bid Price Requirement.","The extension follows prior milestones, including a previous extension granted on July 28, 2025 for compliance by August 12 (equity) and August 29 (bid price)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139217,"accession_number":"0001615219-25-000117","cik":1615219,"company_name":"Decoy Therapeutics Inc.","ticker":"DCOY","form_type":"8-K","filed_at":"2025-08-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Salarius Pharmaceuticals files $2.6M ATM equity offering via Ladenburg Thalmann","event_type":"other_material","confidence":"high","bullets":["Offering of up to $2.6M of common stock at-the-market under existing S-3 shelf registration.","Sales agent is Ladenburg Thalmann & Co. Inc.; prospectus supplement dated August 22, 2025.","Shares have $0.0001 par value; legal opinion of Hogan Lovells included as Exhibit 5.1.","Proceeds intended for general corporate purposes; no specific use stated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139207,"accession_number":"0001615219-25-000115","cik":1615219,"company_name":"Decoy Therapeutics Inc.","ticker":"DCOY","form_type":"8-K/A","filed_at":"2025-08-26T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Salarius amends merger with Decoy; legacy holders diluted to 7.6%","event_type":"m_and_a","confidence":"high","bullets":["Effective ownership post-merger: Salarius legacy holders 7.6%, Decoy holders 92.4% (pre-Qualified Financing).","Salarius valuation reduced from $4.6M to $2.31M in Amendment 2; Decoy valued at $28M.","Qualified Financing requires minimum $6M; expected $8M from 1,470,588 shares at $5.44/share.","Amendment 4 removes threshold for anti-dilution adjustments; applies until Nasdaq listing & shareholder approval.","Merger accounted for as reverse asset acquisition with Decoy as accounting acquirer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139216,"accession_number":"0001628280-25-041043","cik":1615219,"company_name":"Decoy Therapeutics Inc.","ticker":"DCOY","form_type":"8-K","filed_at":"2025-08-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Salarius-Decoy merger update: legacy holders ~7.6% stake, $6M minimum financing required","event_type":"m_and_a","confidence":"high","bullets":["Step one: Decoy stockholders receive ~92.4% of Salarius; legacy holders ~7.6% based on exchange ratio.","Merger closing conditioned on minimum $6.0M Qualified Financing and continued Nasdaq listing.","Step two requires stockholder approval for Preferred Stock conversion; Nasdaq initial listing must precede.","Decoy's lead pan-coronavirus prophylactic IND planned H1 2026; funded by Gates Foundation and BARDA.","Combined company to explore P-PROTACs using Salarius' SP-3164, initial focus on metastatic colorectal cancer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139215,"accession_number":"0001615219-25-000107","cik":1615219,"company_name":"Decoy Therapeutics Inc.","ticker":"DCOY","form_type":"8-K","filed_at":"2025-08-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Salarius Pharma CEO David J. Arthur resigns; CFO Mark J. Rosenblum named acting CEO","event_type":"leadership","confidence":"high","bullets":["David J. Arthur resigned as CEO effective Aug 17, 2025; not due to any disagreement with the company.","Mark J. Rosenblum appointed acting CEO, continuing as EVP and CFO; no new employment agreement.","Consulting agreement with Arthur terminated immediately upon resignation.","Rosenblum has served as EVP Finance/CFO since Sep 2019; previously CFO of Advaxis, Inc.","Company working to finalize previously announced merger with Decoy Therapeutics Inc."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139214,"accession_number":"0001615219-25-000101","cik":1615219,"company_name":"Decoy Therapeutics Inc.","ticker":"DCOY","form_type":"8-K","filed_at":"2025-08-15T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Salarius Pharmaceuticals effects 1-for-15 reverse stock split to regain Nasdaq compliance","event_type":"other_material","confidence":"high","bullets":["Reverse split effective 5:00 p.m. ET on August 15, 2025; trading on split-adjusted basis from August 18, 2025.","Shares outstanding reduced from ~7.6M to ~509,000; no fractional shares, cash in lieu paid.","New CUSIP number 79400X503; authorized shares and par value unchanged.","Split approved by stockholders at July 8, 2025 special meeting; ratio set by Board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139213,"accession_number":"0001615219-25-000080","cik":1615219,"company_name":"Decoy Therapeutics Inc.","ticker":"DCOY","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["2.02","3.02"],"status":"ready","headline":"Salarius Pharma expects Q2 net loss ~$900K, cash $800K; raises $3.8M via equity line","event_type":"earnings","confidence":"high","bullets":["Preliminary Q2 2025 net loss ~$900,000; cash at June 30 was $800,000.","Issued 5.5M shares under equity line for ~$3.8M gross proceeds post-quarter.","As of July 30, 2025, pro forma cash ~$4.5M after issuance.","Unregistered sale to C/M Capital Master Fund LP under purchase agreement.","Preliminary results are subject to adjustment; not yet audited."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139212,"accession_number":"0001615219-25-000078","cik":1615219,"company_name":"Decoy Therapeutics Inc.","ticker":"DCOY","form_type":"8-K","filed_at":"2025-07-29T23:59:59+00:00","items":["1.01","3.03","9.01"],"status":"ready","headline":"Salarius amends Decoy merger: removes $2M threshold, changes conversion price adjustment","event_type":"m_and_a","confidence":"high","bullets":["Fourth Amendment dated July 29, 2025 removes $2M threshold for 'subsequent financing' triggering conversion adjustment.","Conversion price adjustment changes from weighted average to actual per share offering price in subsequent financings.","One-year limitation on conversion ratio adjustments eliminated; adjustments apply until stockholder approval and Nasdaq listing standards met.","Amendments intended to induce holders of Decoy convertible/non-convertible notes to consent and convert."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139211,"accession_number":"0001615219-25-000076","cik":1615219,"company_name":"Decoy Therapeutics Inc.","ticker":"DCOY","form_type":"8-K","filed_at":"2025-07-28T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Nasdaq Hearings Panel grants SLRX additional extension to regain listing compliance by August 2025","event_type":"other_material","confidence":"high","bullets":["Equity Standard compliance deadline extended to mid-August 2025 from late July.","Minimum Bid Price compliance deadline extended to late August 2025 from early August.","Company previously effected a reverse stock split within past year, affecting eligibility for standard compliance periods.","Failure to meet milestones could result in delisting from Nasdaq.","Company's common stock (SLRX) remains listed pending hearing process resolution."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139210,"accession_number":"0001615219-25-000072","cik":1615219,"company_name":"Decoy Therapeutics Inc.","ticker":"DCOY","form_type":"8-K","filed_at":"2025-07-21T23:59:59+00:00","items":["1.01","3.03","9.01"],"status":"ready","headline":"Salarius amends merger agreement to allow Decoy noteholders to exchange debt for Series B Preferred","event_type":"m_and_a","confidence":"high","bullets":["Third Amendment dated July 18, 2025 allows holders of Decoy promissory notes to exchange debt for newly created Series B Non-Voting Convertible Preferred Stock.","Series B converts into common shares at a ratio based on the per-share offering price in the required $6.0M Qualified Financing.","Pre-Qualified Financing ownership percentages unchanged: Salarius legacy stockholders retain 7.6%, Decoy legacy stockholders retain 92.4%.","Mandatory redemption requires 50% of net proceeds from ATM draws or equity line of credit to redeem Series B shares until fully redeemed.","Series B conversion requires stockholder approval and Nasdaq initial listing satisfaction; automatic conversion one year after conversion approval date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139209,"accession_number":"0001615219-25-000069","cik":1615219,"company_name":"Decoy Therapeutics Inc.","ticker":"DCOY","form_type":"8-K","filed_at":"2025-07-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Salarius gets additional Nasdaq extension to late July 2025 for equity standard compliance","event_type":"regulatory","confidence":"high","bullets":["Nasdaq Hearings Panel extended deadline to regain Equity Standard compliance to late July 2025.","Minimum Bid Price Requirement must be met by early August 2025.","On Jan 13, 2025, Salarius announced a merger agreement with Decoy Therapeutics; combined company to be named Decoy Therapeutics.","Failure to meet milestones could trigger delisting; previous deadline for equity standard was early July 2025.","Merger closing conditions remain; Decoy's CEO Rick Pierce will lead combined company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139208,"accession_number":"0001615219-25-000066","cik":1615219,"company_name":"Decoy Therapeutics Inc.","ticker":"DCOY","form_type":"8-K","filed_at":"2025-07-08T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Salarius stockholders approve reverse stock split and Nasdaq 20% share issuance","event_type":"other_material","confidence":"high","bullets":["Reverse stock split approved at ratio of 1:4 to 1:40; Board retains discretion on timing and exact ratio.","Nasdaq 20% issuance proposal passed, authorizing shares under December 2024 purchase agreement with C/M Capital Master Fund, LP.","Adjournment proposal passed but was not needed; quorum of 37.10% (789,213 of 2,127,286 shares) was present.","Reverse split vote: 561,364 for, 224,901 against; issuance vote: 124,631 for, 73,764 against (589,723 broker non-votes)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156772,"accession_number":"0001615219-25-000064","cik":1615219,"company_name":"Decoy Therapeutics Inc.","ticker":"DCOY","form_type":"8-K","filed_at":"2025-06-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Salarius gets Nasdaq extension to regain listing compliance; milestones set for July/August 2025","event_type":"regulatory","confidence":"high","bullets":["Nasdaq Hearings Panel granted extension to comply with Minimum Bid Price and Equity Standards.","Must regain compliance with Equity Standard (minimum $2.5M stockholders' equity) by early July 2025.","Must regain compliance with Minimum Bid Price (closing bid $1.00) by early August 2025.","Previously received delisting notices for non-compliance with both rules; hearing held June 3, 2025.","Failure to meet milestones may result in revocation of extension and delisting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156771,"accession_number":"0001615219-25-000062","cik":1615219,"company_name":"Decoy Therapeutics Inc.","ticker":"DCOY","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Salarius cuts merger valuation from $4.6M to $2.31M; legacy holders drop to 7.6%","event_type":"m_and_a","confidence":"high","bullets":["Parent Valuation reduced to $2.31M, down from $4.6M in original Jan 2025 merger agreement.","Legacy Salarius stockholders retention cut to 7.6% from 14.1%; Decoy holders rise to 92.4%.","Exchange ratio change adds ~17M more shares to Decoy stockholders at closing.","Series A Preferred includes one-year anti-dilution protection and Nasdaq conversion restrictions.","Automatic conversion conditioned on Nasdaq listing approval and stockholder vote per Rule 5635."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156770,"accession_number":"0001615219-25-000045","cik":1615219,"company_name":"Decoy Therapeutics Inc.","ticker":"DCOY","form_type":"8-K","filed_at":"2025-04-25T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Salarius Pharma receives Nasdaq delisting notice for bid price non-compliance; merger with Decoy planned","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notice on April 23, 2025 for failing minimum $1.00 bid price for 30 consecutive business days.","Ineligible for compliance period due to prior reverse stock split; also non-compliant with $2.5M equity standard.","Unless appeal by April 30, 2025, suspension and delisting scheduled for May 2, 2025; company intends to appeal.","Plans to present merger with Decoy Therapeutics Inc. to regain compliance at Nasdaq Hearings Panel."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175179,"accession_number":"0001615219-25-000040","cik":1615219,"company_name":"Decoy Therapeutics Inc.","ticker":"DCOY","form_type":"8-K","filed_at":"2025-03-28T23:59:59+00:00","items":["1.01","3.01","9.01"],"status":"ready","headline":"Salarius amends merger fixing 14.1% legacy ownership; Nasdaq delisting risk from $2.5M equity shortfall","event_type":"regulatory","confidence":"high","bullets":["Amendment eliminates cash-based exchange ratio adjustment; legacy Salarius stockholders retain 14.1%, Decoy holders 85.9% of combined company.","Nasdaq notified Salarius on March 26, 2025 it fails minimum $2.5M stockholders' equity for continued listing.","Company must submit a compliance plan by May 12, 2025; if accepted, Nasdaq may grant up to 180 days to regain compliance.","If plan rejected or compliance not regained, Nasdaq may delist; Salarius can request a hearing for up to 180 additional days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175178,"accession_number":"0001615219-25-000033","cik":1615219,"company_name":"Decoy Therapeutics Inc.","ticker":"DCOY","form_type":"8-K","filed_at":"2025-03-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Salarius Pharmaceuticals files prospectus supplement for ATM offering of up to $417,000","event_type":"other_material","confidence":"high","bullets":["Filed prospectus supplement on March 10, 2025 for at-the-market offering of up to $417,000 of common stock.","Offering conducted through Ladenburg Thalmann & Co. under existing S-3 registration statement (333-266589).","Legal opinion from Hogan Lovells US LLP included as Exhibit 5.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}